LABORATORY PARAMETERS OF BONE MINERAL DISEASE IN RENAL TRANSPLANT PATIENTS

Abstract

E levated iPTH level is very common among renal allograft patients even with a well functioning renal transplant. The KDIGO 2009 guidelines recommend monitoring calcium and phosphorous levels every 6–12 months and PTH once after the immediate post-transplant period.We suggest that it may be important to monitor not only patients with reduced graft function but also patients with normal graft function after transplantation for recognizing disturbances in mineral and bone metabolism. At this time, there are no well established therapeutic approaches that would provide bone preserving or anabolic effects with high degree of certainty. However, vitamin D analogs and bisphosphonates are often used for the treatment of MBD after kidney transplantation. Whereas more studies are needed to examine the effects of different therapeutic interventions on bone disorders after kidney transplantation.